Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Cullinan Oncology, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results Phase 3 first-line study of zipalertinib in EGFR exon 20 insertion mutation non-small-cell lung cancer patients open to enrollment Initial monotherapy clinical data for CLN-619 presented at ASCO 2023 Annual Meeting; initiated monotherapy expansion cohorts in endometrial and cervical cancers First patient dosed in Phase 1study of CLN-978 in relapsed/refractory B Cell non-Hodgkin lymphoma Cash and investment position of $512.1 million as of June 30, 2023 continues to provide runway into 2026 CAMBRIDGE, Mass., August 10, 2023 -- Cullinan Oncology, Inc. a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today reported on recent and upcoming business highlights and an..."
07/05/2023 4 Trigilio Jeffrey (CFO) has filed a Form 4 on Cullinan Oncology, Inc.
Txns: Granted 2,340 shares @ $9.08, valued at $21.2k
06/29/2023 4 AHMED NADIM (President and CEO) has filed a Form 4 on Cullinan Oncology, Inc.
Txns: Sold 759 shares @ $11.4, valued at $8.7k
06/12/2023 4 Ebeling Thomas (Director) has filed a Form 4 on Cullinan Oncology, Inc.
Txns: Granted 18,450 options to buy @ $13, valued at $239.9k
06/12/2023 4 Rosenberg Anthony (Director) has filed a Form 4 on Cullinan Oncology, Inc.
Txns: Granted 18,450 options to buy @ $13, valued at $239.9k
06/12/2023 4 Webster Stephen W (Director) has filed a Form 4 on Cullinan Oncology, Inc.
Txns: Granted 18,450 options to buy @ $13, valued at $239.9k
06/12/2023 4 Martin Anne-Marie (Director) has filed a Form 4 on Cullinan Oncology, Inc.
Txns: Granted 18,450 options to buy @ $13, valued at $239.9k
06/08/2023 4 Michaelson Jennifer (Chief Development Officer) has filed a Form 4 on Cullinan Oncology, Inc.
Txns: Sold 11,900 shares @ $12.31, valued at $146.5k
Sold 100 shares @ $12.4, valued at $1.2k
Exercised 11,900 options to buy @ $4.3, valued at $51.2k
Exercised 100 options to buy @ $4.3, valued at $430
06/06/2023 144 Form 144 - Report of proposed sale of securities:
05/25/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023"
05/24/2023 4 AHMED NADIM (President and CEO) has filed a Form 4 on Cullinan Oncology, Inc.
Txns: Sold 707 shares @ $9.15, valued at $6.5k
05/19/2023 4 Michaelson Jennifer (Chief Development Officer) has filed a Form 4 on Cullinan Oncology, Inc.
Txns: Sold 239 shares @ $8.76, valued at $2.1k
05/19/2023 4 Jones Jeffrey Alan (Chief Medical Officer) has filed a Form 4 on Cullinan Oncology, Inc.
Txns: Sold 394 shares @ $8.76, valued at $3.5k
05/19/2023 4 SUMER JACQUELYN L (Chief Legal Officer) has filed a Form 4 on Cullinan Oncology, Inc.
Txns: Sold 291 shares @ $8.76, valued at $2.5k
05/19/2023 4 Trigilio Jeffrey (CFO) has filed a Form 4 on Cullinan Oncology, Inc.
Txns: Sold 399 shares @ $8.76, valued at $3.5k
05/19/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/16/2023 4 Michaelson Jennifer (Chief Development Officer) has filed a Form 4 on Cullinan Oncology, Inc.
Txns: Sold 193 shares @ $8.78, valued at $1.7k
05/16/2023 4 Trigilio Jeffrey (CFO) has filed a Form 4 on Cullinan Oncology, Inc.
Txns: Sold 347 shares @ $8.78, valued at $3k
05/11/2023 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results"
04/26/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/21/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/21/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/20/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/20/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/20/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/20/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/14/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/14/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/27/2023 4 Trigilio Jeffrey (CFO) has filed a Form 4 on Cullinan Oncology, Inc.
Txns: Sold 399 shares @ $11.32, valued at $4.5k
03/27/2023 4 Jones Jeffrey Alan (Chief Medical Officer) has filed a Form 4 on Cullinan Oncology, Inc.
Txns: Sold 390 shares @ $11.32, valued at $4.4k
03/27/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy